Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Drospirenone

FDA-approved product (tablet, oral), marketed as Drospirenone, Slynd.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Drospirenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Progestogens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Drospirenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Drospirenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

    NCT07792408 · start 2026-08-28

    Registered record
    Registry ID
    NCT07792408
    Conditions
    Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Interventions
    VX-407; LNG/EE; NGM/EE; NET/EE; DRSP/EE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-28
    Completion
    2027-03-20
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutosomal Dominant Polycystic Kidney Disease (ADPKD)
    InterventionVX-407; LNG/EE; NGM/EE; NET/EE +1 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • Clinical Efficacy And Safety of Dydrogesterone In The Treatment Of Abnormal Uterine Bleeding During Puberty

    NCT07703488 · start 2026-07-06

    Registered record
    Registry ID
    NCT07703488
    Conditions
    Abnormal Uterine Bleeding (AUB); Ovulation Dysfunction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-07-06
    Completion
    2028-07-28
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbnormal Uterine Bleeding (AUB); Ovulation Dysfunction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS

    NCT07242131 · start 2025-12-01

    Registered record
    Registry ID
    NCT07242131
    Conditions
    Polycystic Ovary Syndrome (PCOS)
    Interventions
    Combined Oral Contraceptive (Ethinylestradiol 0.03 mg + Drospirenone 3 mg); Inositol mid-level volume; Dydrogesterone Pill
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-12-01
    Completion
    2026-06-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome (PCOS)
    InterventionCombined Oral Contraceptive (Ethinylestradiol 0.03 mg + Drospirenone 3 mg); Inositol mid-level volume; Dydrogesterone Pill
    PhaseNot applicable
    Registry statusRecruiting

  • A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants

    NCT07235774 · start 2025-11-05

    Registered record
    Registry ID
    NCT07235774
    Conditions
    Healthy Adult Female Participants
    Interventions
    Vorasidenib; DRSP/EE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-11-05
    Completion
    2026-03-13
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Female Participants
    InterventionVorasidenib; DRSP/EE
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

    NCT06820307 · start 2025-02-25

    Registered record
    Registry ID
    NCT06820307
    Conditions
    Pain
    Interventions
    Suzetrigine; DRSP/EE; NGM/EE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-25
    Completion
    2025-04-29
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionSuzetrigine; DRSP/EE; NGM/EE
    PhasePhase 1
    Registry statusCompleted

  • Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!

    NCT06608186 · start 2024-10-01

    Registered record
    Registry ID
    NCT06608186
    Conditions
    PCOS (Polycystic Ovary Syndrome)
    Interventions
    Cetrorelix drug; Drospirenone drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2024-10-01
    Completion
    2025-01-19
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS (Polycystic Ovary Syndrome)
    InterventionCetrorelix drug; Drospirenone drug
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

    NCT06250205 · start 2024-02-05

    Registered record
    Registry ID
    NCT06250205
    Conditions
    Healthy Volunteers
    Interventions
    Obicetrapib; Obicetrapib + Drospirenone / Ethinyl Estradiol (COC); Drospirenone / Ethinyl Estradiol (COC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-02-05
    Completion
    2024-04-26
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionObicetrapib; Obicetrapib + Drospirenone / Ethinyl Estradiol (COC); Drospirenone / Ethinyl Estradiol (COC)
    PhasePhase 1
    Registry statusCompleted

  • A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood

    NCT05934942 · start 2023-09-08

    Registered record
    Registry ID
    NCT05934942
    Conditions
    Healthy
    Interventions
    Yasmin®; BI 1358894
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-09-08
    Completion
    2024-02-08
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionYasmin®; BI 1358894
    PhasePhase 1
    Registry statusTerminated

  • A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

    NCT05985590 · start 2023-08-18

    Registered record
    Registry ID
    NCT05985590
    Conditions
    Healthy Volunteers
    Interventions
    BMS-986278; Drospirenone/Ethinyl Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-08-18
    Completion
    2023-12-11
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBMS-986278; Drospirenone/Ethinyl Estradiol
    PhasePhase 1
    Registry statusCompleted

  • Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder

    NCT05098574 · start 2023-02-03

    Registered record
    Registry ID
    NCT05098574
    Conditions
    Premenstrual Dysphoric Disorder; Bipolar Disorder
    Interventions
    Yaz; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-02-03
    Completion
    2024-04-11
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Dysphoric Disorder; Bipolar Disorder
    InterventionYaz; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Aspirin for the Management of Endometriosis-associated Pelvic Pain

    NCT05156879 · start 2021-12-23

    Registered record
    Registry ID
    NCT05156879
    Conditions
    Pelvic Pain
    Interventions
    Aspirin; Drospirenone ethinyl estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-12-23
    Completion
    2025-06
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPelvic Pain
    InterventionAspirin; Drospirenone ethinyl estradiol
    PhasePhase 4
    Registry statusUnknown

  • The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study

    NCT05135013 · start 2021-11-16

    Registered record
    Registry ID
    NCT05135013
    Conditions
    Observational Study
    Interventions
    Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-11-16
    Completion
    2022-03-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObservational Study
    InterventionDydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
    PhaseNot recorded
    Registry statusUnknown

  • The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics

    NCT04831151 · start 2021-03-01

    Registered record
    Registry ID
    NCT04831151
    Conditions
    Polycystic Ovary Syndrome
    Interventions
    Yasmin; Diane-35
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-03-01
    Completion
    2023-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome
    InterventionYasmin; Diane-35
    PhaseNot applicable
    Registry statusUnknown

  • Binge Eating & Birth Control

    NCT04278755 · start 2020-09-24

    Registered record
    Registry ID
    NCT04278755
    Conditions
    Bulimia Nervosa; Binge Eating; Eating Disorders; Binge-Eating Disorder
    Interventions
    Drospirenone-Ethinyl Estradiol Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-09-24
    Completion
    2022-05-17
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBulimia Nervosa; Binge Eating; Eating Disorders; Binge-Eating Disorder
    InterventionDrospirenone-Ethinyl Estradiol Oral Tablet
    PhasePhase 2
    Registry statusTerminated

  • Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study

    NCT03512860 · start 2018-04-12

    Registered record
    Registry ID
    NCT03512860
    Conditions
    Contraception
    Interventions
    E4/DRSP; VAL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-12
    Completion
    2018-10-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionE4/DRSP; VAL
    PhasePhase 1
    Registry statusCompleted